The combination of abacavir sulfate, dolutegravir sodium, and lamivudine is a single-tablet regimen used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg [1]. This regimen is a complete treatment option that can be used in individuals who have no known history of resistance to any of the three antiretroviral agents in the combination [1].
What is the brand name for this HIV treatment?
The combination of abacavir sulfate, dolutegravir sodium, and lamivudine is marketed under the brand name Triumeq [2].
How does this HIV drug combination work?
Triumeq is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks an enzyme called integrase, which HIV needs to insert its genetic material into the host cell's DNA. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that works by interfering with the reverse transcriptase enzyme, another crucial enzyme for HIV replication. Lamivudine is also an NRTI that similarly inhibits reverse transcriptase [1]. By blocking these key viral enzymes, the combination reduces the amount of HIV in the body (viral load) and increases the number of CD4 cells, which are important for fighting infection [1].
What are the potential side effects of abacavir sulfate, dolutegravir sodium, and lamivudine?
Common side effects associated with Triumeq include insomnia, nausea, headache, and fatigue [1]. A serious potential side effect is a hypersensitivity reaction (HSR) to abacavir, which can be severe and even life-threatening. Symptoms of HSR can include fever, rash, fatigue, nausea, vomiting, diarrhea, abdominal pain, shortness of breath, cough, and sore throat. Screening for the HLA-B*5701 genetic variant is recommended before starting treatment with abacavir to identify individuals at higher risk of HSR. If HSR is suspected, treatment should be stopped immediately [1]. Other serious side effects can include liver problems, lactic acidosis, and worsening of hepatitis B infection if a patient also has it [1].
When can patent protection for Triumeq expire?
Patent expiration timelines for pharmaceutical drugs are complex and can involve multiple patents covering different aspects of the drug, formulation, or manufacturing process. Information regarding specific patent expiration dates for Triumeq and its components can be found through specialized resources. For instance, DrugPatentWatch.com tracks patent information for pharmaceuticals [3]. The patent landscape for such a combination therapy would include patents for each individual drug and potentially patents for the fixed-dose combination itself.
Who are the competitors for this type of HIV treatment?
The HIV treatment landscape is competitive, with numerous antiretroviral drugs and combination therapies available. Competitors include other single-tablet regimens and multi-pill regimens that utilize different drug classes or combinations of drugs to manage HIV. These may include INSTI-based regimens, protease inhibitor-based regimens, and other NRTI combinations [1].